Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 20;13(2):341–352. doi: 10.1158/1535-7163.MCT-13-0478

Figure 2. Mahanine inhibits ligand-independent AR transactivation.

Figure 2

LNCaP cells were co-transfected with AR-NTD-Gal4DBD expression vector and Gal4UAS-TATA-luciferase reporter construct and treated with (A) Forskolin (FSK) (50µM) or (B) IL6 (50ng/ml) in the absence and presence of mahanine (10µM) for 24 hours. Luciferase activity was measured after normalization with Renilla luciferase. Western blot analysis was performed to show the levels of the AR-NTD-Gal4DBD fusion protein. (C) LNCaP cells were co-transfected with VP16 activation domain-Gal4DBD fusion protein and Gal4UAS-TATA-luciferase reporter and treated with mahanine (10µM) for 24 hours. Luciferase activity was measured after normalization with Renilla luciferase. LNCaP cells were transfected with ARR3-TK-luciferase reporter construct and treated with (D) Forskolin (FSK) (50µM) or (E) IL6 (50ng/ml) in the absence and presence of mahanine (10µM) for 24 hours. Luciferase activity was measured after normalization with Renilla luciferase. Western blot analysis was performed to show the levels of the endogenous AR. Columns, mean of three independent experiments with quadruplicate samples; bars, SEM. ***p value<0.0001.